Tag Archives: semaglutide

Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction–associated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide. Traditionally, clinicians have associated MASLD with obesity, insulin resistance, and type 2 diabetes, often using body mass index (BMI) and A1C as screening triggers. However, an important shift is occurring …

The potential link between GLP‑1 therapies and depression has sparked growing interest among clinicians and researchers. If you’ve ever wondered whether glucagon‑like peptide‑1 (GLP‑1) receptor agonists could positively influence mood, you’re not alone. Early research suggests these medications may ease depressive symptoms by dampening inflammation and influencing brain signaling, though …

Could a diabetes medication help women with PCOS regain control of their cycles and metabolism? GLP‑1 receptor agonists, best known for treating type 2 diabetes and obesity, are showing promise for women with polycystic ovary syndrome (PCOS). These medications may support weight loss, improve insulin resistance, and even lead to …

The class of medications known as GLP-1 receptor agonists — commonly prescribed for type 2 diabetes and increasingly used for weight loss — may offer more than just metabolic benefits. Growing evidence indicates that GLP-1 drugs could play a role in protecting the brain. Could this mean a dual benefit …